The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Temozolomide, a Novel Alkylating Agent with Activity in the Central Nervous System, May Improve the Treatment of Advanced Metastatic Melanoma
Open accessAbstract
Temozolomide (TMZ) is the first new chemotherapy agent to be approved for the treatment of high-grade malignant gliomas in more than 20 years. This novel oral alkylating agent has demonstrated promising activity not only in brain tumors, but in a variety of solid tumors, including malignant melanoma. TMZ is 100% bioavailable when taken orally and, because of its small size and lipophilic properties, it is able to cross the blood-brain barrier. Concentrations in the central nervous system are approximately 30% of plasma concentrations. Once it has entered the central nervous system, TMZ can be spontaneously converted to the active metabolite. These pharmacologic properties make it an ideal agent for treating central nervous system malignancies. In patients with advanced metastatic melanoma, brain metastases are a major cause of treatment failure. In this setting, TMZ has been shown to be as effective as dacarbazine, with a similar safety profile. More importantly, there is evidence to suggest that TMZ-treated patients have a lower incidence of central nervous system relapse compared with dacarbazine-treated patients. Therefore, TMZ is actively being investigated for the treatment and prevention of brain metastases in melanoma patients. TMZ may become an important part of treatment regimens for advanced metastatic melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,048
Middleton, M. R., Grob, J. J., Aaronson, N., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M., Aamdal, S., Cebon, J., Coates, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.158 · Cited by 1,272
Newlands, E. S., Stevens, M. F. G., Wedge, S. R., Wheelhouse, R. T., & Brock, C. (1997) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(97)90019-0 · Cited by 817
Chapman, P. B., Einhorn, L. H., Meyers, M. L., Saxman, S., Destro, A. N., Panageas, K. S., Begg, C. B., Agarwala, S. S., Schuchter, L. M., Ernstoff, M. S., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2745 · Cited by 764
Self-citationYung, W. K. A., Prados, M. D., Yaya-Tur, R., Rosenfeld, S. S., Brada, M., Friedman, H. S., Albright, R., Olson, J., Chang, S. M., O'Neill, A. M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2762 · Cited by 761
Cancer principles and practice of oncology
Kerin, M. J. (1997) · Surgical Oncology · doi:10.1016/s0960-7404(97)90012-8 · Cited by 739
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)
Newlands, E., Blackledge, G., Slack, J., Rustin, G., Smith, D., Stuart, N., Quarterman, C., Hoffman, R., Stevens, M., Brampton, M., et al. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.57 · Cited by 488
Friedman, H. S., McLendon, R. E., Kerby, T., Dugan, M., Bigner, S. H., Henry, A. J., Ashley, D. M., Krischer, J., Lovell, S., Rasheed, K., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3851 · Cited by 423
Stevens, M. F. G., Hickman, J. A., Langdon, S. P., Chubb, D., Vickers, L. M., Stone, R., BAIG, G. U., Goddard, C. P., Gibson, N. W., & Slack, J. A. (1987) · PubMed · Cited by 387
Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma
Friedman, H. S., Petros, W. P., Friedman, A. H., Schaaf, L. J., Kerby, T., Lawyer, J., Parry, M., Houghton, P. J., Lovell, S., Rasheed, K., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1516 · Cited by 357
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Seipp, C. A., Einhorn, J. H., White, D. E., & Steinberg, S. M. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.968 · Cited by 312
Phase I trial of temozolomide using an extended continuous oral schedule.
Brock, C., Newlands, E. S., Wedge, S. R., Bower, M., Evans, H. S., Colquhoun, I. R., Roddie, M., Glaser, M. G., Brampton, M., & Rustin, G. J. S. (1998) · PubMed · Cited by 284
Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.
Bleehen, N. M., Newlands, E. S., Lee, S. M., Thatcher, N., Selby, P., Calvert, A. H., Rustin, G. J., Brampton, M., & Stevens, M. F. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.4.910 · Cited by 282
O'Reilly, S. M., Newlands, E. S., Brampton, M., Glaser, M. G., Rice-Edwards, J. M., Illingworth, R. D., Richards, P. G., Kennard, C., Colquhoun, I. R., Lewis, P., et al. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80198-4 · Cited by 277
Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma
Bower, M., Newlands, E. S., Bleehen, N. M., Brada, M., Begent, R. J. H., Calvert, H., Colquhoun, I., Lewis, P., & Brampton, M. H. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050691 · Cited by 221
Keilholz, U., Goey, S. H., Punt, C. J., Proebstle, T. M., Salzmann, R., Scheibenbogen, C., Schadendorf, D., Liénard, D., Enk, A., Dummer, R., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2579 · Cited by 193
Intravenous carboplatin for recurrent malignant glioma: a phase II study.
Yung, W. K., Mechtler, L., & Gleason, M. J. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.5.860 · Cited by 179
The charing cross hospital experience with temozolomide in patients with gliomas
Newlands, E. S., O'Reilly, S. M., Glaser, M. G., Bower, M., Evans, H., Brock, C., Brampton, M. H., Colquhoun, I., Lewis, P., Rice-Edwards, J. M., et al. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00258-4 · Cited by 159
Khayat, D., Borel, C., Tourani, J. M., Benhammouda, A., Antoine, É.-C., Rixe, O., Vuillemin, E., Bazex, P. A., Thill, L., & Franks, R. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2173 · Cited by 150
Phase I study of temozolomide in paediatric patients with advanced cancer
on the behalf of the United Kingdom Children's Cancer Study Group, Estlin, E., Lashford, L. S., Ablett, S., Price, L., Gowing, R., Gholkar, A. R., Kohler, J. A., Lewis, I., Morland, B. J., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.555 · Cited by 140
Fulton, D. S., Urtasun, R. C., & Forsyth, P. A. (1996) · Journal of Neuro-Oncology · doi:10.1007/bf00177478 · Cited by 121
Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients.
Huncharek, M. S., & Muscat, J. E. (1998) · PubMed · Cited by 114
Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study.
Jeremic, B. M., Grujičić, D., Jevremovic, S., Stanisavljevic, B., Milojevic, L., Djuric, L. J., & Mijatovic, L. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1074 · Cited by 98
Middleton, M. R., Lunn, J., Morris, C., Rustin, G. J. S., Wedge, S. R., Brampton, M., Lind, M., Lee, S. M., Newell, D. R., Bleehen, N. M., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.654 · Cited by 86
Cited by
Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells
Kanzawa, T., Germano, I. M., Komata, T., Ito, H., Kondo, Y., & Kondo, S. (2004) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401359 · Cited by 986
Shi, L., Chen, J., Yang, J., Pan, T., Zhang, S., & Wang, Z. (2010) · Brain Research · doi:10.1016/j.brainres.2010.07.009 · Cited by 343
Tomar, M. S., Kumar, A., Srivastava, C., & Shrivastava, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188616 · Cited by 325
Triazene compounds: Mechanism of action and related DNA repair systems
MARCHESI, F., TURRIZIANI, M., TORTORELLI, G., AVVISATI, G., TORINO, F., & DEVECCHIS, L. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.08.003 · Cited by 299
Hombach-Klonisch, S., Mehrpour, M., Shojaei, S., Harlos, C., Pitz, M., Hamai, A., Siemianowicz, K., Likus, W., Wiechec, E., Toyota, B. D., et al. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.017 · Cited by 292
Metadata
- Authors
- Agarwala, S. S., & Kirkwood, J. M.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-04-01
- Volume
- 5
- Issue
- 2
- Pages
- 144-151
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2053668604
- Cited by
- 330
- References
- 25
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.